Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant newcastle disease virus inactivated vaccine (A-VII strain)
- Development stage
- Unknown
- Lead developer
- Youbang Pharmaceutical
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Recombinant Newcastle disease virus inactivated vaccine (A-VII strain) is a veterinary vaccine developed by Youbang Pharmaceutical for the prevention of Newcastle disease in poultry, including chickens and waterfowl. The vaccine utilizes a recombinant Newcastle disease virus (NDV) of the A-VII genotype, which is inactivated to ensure safety while maintaining immunogenicity. The A-VII strain is specifically engineered to provide high-level protection against the virulent genotype VII NDV strains currently circulating in the field. Upon administration, the vaccine stimulates the production of neutralizing antibodies against the NDV surface proteins, thereby preventing infection and reducing viral shedding in the event of exposure. It is an approved product in the Chinese veterinary market.
- Other names
- 重组新城疫病毒灭活疫苗（A-Ⅶ株）Newcastle disease virus inactivated vaccine (A-VII strain)
Beyond the preview
Go deeper on recombinant newcastle disease virus inactivated vaccine (A-VII strain).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant newcastle disease virus inactivated vaccine (A-VII strain).